CA3251985A1 - HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF AN ERK5-MEDICATED DISEASE - Google Patents
HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF AN ERK5-MEDICATED DISEASEInfo
- Publication number
- CA3251985A1 CA3251985A1 CA3251985A CA3251985A CA3251985A1 CA 3251985 A1 CA3251985 A1 CA 3251985A1 CA 3251985 A CA3251985 A CA 3251985A CA 3251985 A CA3251985 A CA 3251985A CA 3251985 A1 CA3251985 A1 CA 3251985A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- solvate
- acceptable salt
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2202199.2 | 2022-02-18 | ||
| GBGB2202199.2A GB202202199D0 (en) | 2022-02-18 | 2022-02-18 | Compounds |
| PCT/GB2023/050369 WO2023156791A1 (en) | 2022-02-18 | 2023-02-17 | Heterocyclic compounds useful for treating a erk5-mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3251985A1 true CA3251985A1 (en) | 2023-08-24 |
Family
ID=80934460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3251985A Pending CA3251985A1 (en) | 2022-02-18 | 2023-02-17 | HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF AN ERK5-MEDICATED DISEASE |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250154157A1 (enExample) |
| EP (1) | EP4479400A1 (enExample) |
| JP (1) | JP2025508435A (enExample) |
| CN (1) | CN119053604A (enExample) |
| AU (1) | AU2023220934A1 (enExample) |
| CA (1) | CA3251985A1 (enExample) |
| GB (1) | GB202202199D0 (enExample) |
| WO (1) | WO2023156791A1 (enExample) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| JP2017504650A (ja) * | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| WO2015117087A1 (en) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| WO2015129927A1 (en) * | 2014-02-26 | 2015-09-03 | Kyorin Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| EP4034132B1 (en) | 2019-09-27 | 2026-02-25 | Dana-Farber Cancer Institute, Inc. | Erk5 degraders as therapeutics in cancer and inflammatory diseases |
-
2022
- 2022-02-18 GB GBGB2202199.2A patent/GB202202199D0/en not_active Ceased
-
2023
- 2023-02-17 US US18/838,492 patent/US20250154157A1/en active Pending
- 2023-02-17 AU AU2023220934A patent/AU2023220934A1/en active Pending
- 2023-02-17 JP JP2024548743A patent/JP2025508435A/ja active Pending
- 2023-02-17 WO PCT/GB2023/050369 patent/WO2023156791A1/en not_active Ceased
- 2023-02-17 CA CA3251985A patent/CA3251985A1/en active Pending
- 2023-02-17 CN CN202380034888.8A patent/CN119053604A/zh active Pending
- 2023-02-17 EP EP23708272.2A patent/EP4479400A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023156791A1 (en) | 2023-08-24 |
| CN119053604A (zh) | 2024-11-29 |
| JP2025508435A (ja) | 2025-03-26 |
| GB202202199D0 (en) | 2022-04-06 |
| AU2023220934A1 (en) | 2024-08-29 |
| US20250154157A1 (en) | 2025-05-15 |
| EP4479400A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11787786B2 (en) | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | |
| EP3609898B1 (en) | Compounds useful as ret inhibitors | |
| EP3283484B1 (en) | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | |
| CN106459035B (zh) | N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途 | |
| AU2021246969A1 (en) | Naphthyridine compounds as inhibitors of Mer tyrosine kinase and AXL tyrosine kinase | |
| EP4373819A1 (en) | Inhibitor compounds | |
| EP4633735A1 (en) | Inhibitory compounds | |
| EP2900235A1 (en) | Indole derivatives | |
| WO2025262192A1 (en) | Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors | |
| US20250154157A1 (en) | Heterocyclic compounds useful for treating a erk5-mediated disease | |
| AU2024369838A1 (en) | Inhibitory compounds | |
| Class et al. | Patent application title: Compounds Useful as RET Inhibitors | |
| CA3020778A1 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| HK40025715B (en) | Benzimidazolone derived inhibitors of bcl6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240814 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250117 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250117 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260210 |